Kristin Van Goor
Executive Director & US Head, Global Regulatory Policy & Innovation Takeda
Seminars
Wednesday 19th August 2026
Panel Discussion: Translating Advances in Disease Biology into Precision-Based Trial Design for Rare & Genetic Kidney Diseases
1:00 pm
- Explore how advances in disease biology and molecular characterization are enabling more precise patient segmentation across rare and genetic kidney diseases
- Discuss how diagnostic strategies, biomarker approaches, and assay validation considerations can support the identification of patients most likely to respond to targeted therapies
- Examine how scientific, industry, and regulatory perspectives can align to inform precision-based trial design, therapeutic development strategies, and future approval pathways
